AMN

(redirected from Adrenomyeloneuropathy)
Also found in: Dictionary, Medical, Wikipedia.
Related to Adrenomyeloneuropathy: adrenoleukodystrophy
AcronymDefinition
AMNAirman (USAF rank)
AMNAdrenomyeloneuropathy (form of neurological disease ALD)
AMNAdvanced Media Network
AMNArt Museum Network
AMNAmerican Medical News
AMNAbstract Machine Notation (formal methods)
AMNArtificial Mains Network
AMNAny Minute Now
AMNAmerican Mobile Nurses
AMNActa Musei Napocensis
AMNAutonomous Maritime Navigation
AMNAnnuity Market News
AMNAnsaldo Meccanico Nucleare
AMNAir Management Node (BFTT/CSTS system on LHD class ships)
AMNAlkali Metal Nitrite
AMNAccess Media Network, Inc.
AMNAmerican Motorcycle Network
AMN(USN Rating) Aviation Structural Mechanic (Hydraulics)
AMNAfghan Mission Network (information system)
AMNAmicale Motocycliste de Nice (French: Friendly Riders of Nice; motorcycle club; Nice, France)
AMNAboriginal Mapping Network (est. 1998; Canada)
References in periodicals archive ?
Clinical aspects of adrenoleukodystrophy and adrenomyeloneuropathy.
the drug-discovery holding of Nutra Pharma, is currently studying the effectiveness of Cobra Venom and Cobratoxin as treatments for Multiple Sclerosis, HIV, Adrenomyeloneuropathy (AMN), pain and rabies.
which today announced that its ReceptoPharm drug candidate has received Ethics Committee approval in the UK to begin a Phase IIb human clinical trial for the treatment of Adrenomyeloneuropathy (AMN), is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases.
Patient 2 was a 51-year-old woman with adrenomyeloneuropathy.
Patients with all clinical subtypes, including childhood ALD, adolescent ALD, adult ALD (cerebral type), adrenomyeloneuropathy, and Addison disease without neurological symptoms, have defects in the ALD gene [2].
OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain announced today that it has selected DNAA, Inc.
Nutra Pharma Corporation (OTCBB:NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that it has received approval in India for its Nyloxin[TM] line of pain relievers.
OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that it has selected MedicinesConsult to serve as the exclusive distributor in Jordan for its Nyloxin-branded pain relievers.
OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its over-the-counter (OTC) pain reliever, Cobroxin, is now available for purchase in CVS.
OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it will be presenting and exhibiting at the upcoming World MoneyShow in Vancouver, Canada, and at the Accredited Members, Inc.
OTCBB:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it will be exhibiting its over-the-counter (OTC) and prescription pain relievers, Nyloxin OTC and Nyloxin Rx, at the 12th IDGA Battlefield Healthcare Summit in Washington, D.